Physician profile
Deanna Denysenko
NPI 1851656383
$1,443.51
in general payments reported to CMS, 2019-2025
26 companies · $399 in 2025
The $399 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.34 · 2020: $92.34 · 2021: $64.99 · 2022: $218 · 2023: $236 · 2024: $378 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Education: $24.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.03 |
| Education | $24.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $204.92 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $181.59 | 2023-2025 | |
| Glaxosmithkline, LLC. | $108.78 | 2023-2024 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $101.94 | 2022-2024 | |
| Tris Pharma INC | $85.30 | 2019-2024 | Dyanavel Xr |
| Alk-Abello, INC | $81.78 | 2023-2025 | Neffy, Ragwitek, Grastek |
| Kaleo, INC. | $73.33 | 2020-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $72.23 | 2025 | |
| Seqirus USA INC | $64.20 | 2022-2025 | Flucelvax |
| Cranial Technologies, INC | $54.51 | 2022-2025 | Doc Band |
| Sobi, INC | $51.50 | 2022-2024 | |
| Corium, LLC | $49.62 | 2022-2023 | Azstarys |
| Ars Pharmaceuticals Operations, INC. | $49.12 | 2025 | Neffy |
| Cipher Pharmaceuticals US LLC | $33.34 | 2025 | Spinosad, Natroba |
| Astrazeneca Pharmaceuticals LP | $30.02 | 2024 | Flumist Quadrivalent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $26.67 | 2024 | Skyclarys |
| Otto Bock Healthcare LP | $24.74 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.91 | 2025 | Strensiq |
| Biomarin Pharmaceutical INC. | $20.15 | 2021 | |
| Cognoa, INC. | $17.35 | 2022 | |
| Phadia US INC. | $16.04 | 2021 | |
| Biomerieux INC | $15.46 | 2025 | Biofire Spotfire Control Station |
| Shire North American Group INC | $15.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.36 | 2021 | |
| Aimmune Therapeutics, INC. | $14.55 | 2023 | |
| Adlon Therapeutics L.P. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Denysenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.